Stock GLMD GALMED PHARMACEUTICALS LTD.
Add to a list
To use this feature you must be a member
Log inSign up

All News Galmed Pharmaceuticals Ltd.

Equities

GLMD

IL0011313900

Delayed Nasdaq
Other stock markets
 03:53:52 2024-04-26 pm EDT 		5-day change 1st Jan Change
0.3851 USD -1.89% Intraday chart for Galmed Pharmaceuticals Ltd. +3.30% -15.36%
Apr. 04 Galmed Pharmaceuticals Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Mar. 15 Galmed Pharmaceuticals Ltd. Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of Nash and Liver Fibrosis CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Galmed Pharmaceuticals Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Galmed Pharmaceuticals Ltd. Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of Nash and Liver Fibrosis
CI
Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis
PR
Galmed Pharmaceuticals : Consolidated Financial Statements - Form 6-K
PU
Galmed Pharmaceuticals Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Sector Update: Health Care Stocks Higher Late Tuesday Afternoon
MT
Sector Update: Health Care
MT
Top Midday Decliners
MT
Galmed Pharmaceuticals Expects Minimum Six Months Delay in Primary Sclerosing Cholangitis Study
MT
Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study
PR
Galmed Pharmaceuticals Ltd. Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal Fibrosis
CI
Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification
AQ
Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification
PR
Galmed Pharmaceuticals: Q2 Earnings Snapshot
AQ
Galmed Pharmaceuticals : 16 Tiomkin St. Tel Aviv 6578317, Israel - Form 6-K
PU
Galmed Pharmaceuticals Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Maxim Upgrades Galmed Pharmaceuticals to Buy From Hold, Price Target is $4
MT
Galmed Pharmaceuticals : Securities Purchase Agreement - Form 6-K
PU
Galmed Pharmaceuticals Announces Pricing of $7 Million Public Offering
AQ
Top Midday Decliners
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GLMD Stock
  4. News Galmed Pharmaceuticals Ltd.